Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Director departure

Anacor Pharmaceuticals, Inc. (ANAC) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/10/2016 8-K Form 8-K - Current report
02/29/2016 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS 2015 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS · Submitted NDA to the FDA on January 7, 2016 seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults · Recognized $69.7 million in total KERYDIN® distribution and commercialization agreement revenues for the year ended December 31, 2015"
11/03/2015 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS · Recognized $21.1 million in total KERYDIN® revenue in the third quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 18.8% over the second quarter of 2015 · Top-line results from the long-term safety study of crisaborole topical ointment, 2%, in patients with mild-to-moderate atopic dermatitis demonstrated a safety profile consistent with that seen in the Phase 3 pivotal studies when used intermittently for up to 12 months · Anacor expects to submit a New Drug Application for crisaborole topical ointment, 2%, to the U.S. Food and Drug Administration in the first quarter of 2016",
"ANACOR PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM LONG-TERM SAFETY STUDY OF CRISABOROLE TOPICAL OINTMENT, 2% IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS · Crisaborole, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor, demonstrated a safety profile consistent with that seen in the Phase 3 pivotal studies when used intermittently for up to 12 months · Anacor now expects to submit a New Drug Application for crisaborole to the U.S. Food and Drug Administration in the first quarter of 2016"
08/06/2015 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS · Recognized $17.8 million in total KERYDIN® revenue in the second quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 47.5% over the first quarter of 2015 · Crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor, achieved statistically significant results on all primary and secondary endpoints in two Phase 3 pivotal studies in patients with mild-to-moderate atopic dermatitis and demonstrated a safety profile consistent with previous studies · Anacor expects to submit a New Drug Application for crisaborole to the U.S. Food and Drug Administration in the first half of 2016"
05/06/2015 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS"
03/12/2015 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS 2014 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS"
11/06/2014 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS"
08/07/2014 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS"
05/07/2014 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS"
03/13/2014 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS 2013 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS"
11/07/2013 8-K Form 8-K - Current report
08/08/2013 8-K Form 8-K - Current report
05/09/2013 8-K Form 8-K - Current report
03/14/2013 8-K Form 8-K - Current report
11/07/2012 8-K Form 8-K - Current report
08/09/2012 8-K Form 8-K - Current report
05/10/2012 8-K Form 8-K - Current report
03/13/2012 8-K Form 8-K - Current report
11/10/2011 8-K Form 8-K - Current report
08/11/2011 8-K Form 8-K - Current report
05/05/2011 8-K Form 8-K - Current report
03/10/2011 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS 2010 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy